Repatha (Evolocumab) in Adolescents Ages 12 to 17: Off-Label Use, Evidence, and Clinical Guidance

Why Evolocumab Is Prescribed Off-Label in Adolescents

Evolocumab blocks PCSK9, a protein that degrades LDL receptors in the liver. Less receptor degradation means more LDL cleared from plasma. The FDA approved evolocumab for HoFH in patients aged 13 and older in 2015, and for adult HeFH and clinical atherosclerotic cardiovascular disease (ASCVD) in the same year. Adolescents aged 12 to 17 with HeFH fall outside those labeled indications, making any prescription in that group off-label [1].

Heterozygous FH affects roughly 1 in 250 individuals worldwide, and untreated adolescents with HeFH can accumulate atherosclerotic plaque decades before a first cardiac event [2]. Because statin therapy is not always sufficient to bring LDL-C to guideline targets in this population, clinicians frequently consider PCSK9 inhibitors as add-on therapy.

Regulatory Status at a Glance

• Approved (on-label): HoFH, age 13 and older, 420 mg subcutaneous monthly [1]
• Off-label: HeFH, age 12 to 17, any dose or schedule
• No approval, any age: primary prevention without a genetic or clinical FH diagnosis

The off-label designation does not mean unapproved for safety. It means the manufacturer has not submitted, or the FDA has not yet reviewed, a formal pediatric indication application for HeFH in this specific age bracket [1].

What "Off-Label" Means in Practice

Physicians prescribe off-label drugs regularly in pediatric medicine. The American Academy of Pediatrics estimates that 50 to 75% of drugs used in children lack a labeled pediatric indication [3]. Off-label prescribing is legal, and insurers may or may not cover it depending on policy and supporting documentation.

Key Clinical Trials in Adolescents

HAUSER-RCT and HAUSER-OLE

The most detailed pediatric data come from the HAUSER program. The HAUSER-RCT enrolled 157 adolescents (ages 10 to 17) with HeFH who were already on optimized statin therapy. Participants received evolocumab 420 mg subcutaneously every 4 weeks or placebo for 24 weeks. The evolocumab arm achieved a placebo-corrected LDL-C reduction of 44.5% (P<0.001) [4]. Triglycerides fell by 16.8% and non-HDL-C by 40.3% in the active arm versus placebo.

The HAUSER open-label extension (HAUSER-OLE) followed completers for an additional 76 weeks. LDL-C reductions were sustained, with no new safety signals emerging over that combined period [5]. Injection-site reactions occurred in approximately 3% of participants, and no serious adverse events were attributed to evolocumab.

The Earlier Phase 2 Pediatric Study (NCT01812603)

A smaller Phase 2 study (N=10, ages 13 to 17) with HoFH used evolocumab 420 mg monthly on top of existing lipid-lowering therapy and documented a mean LDL-C reduction of 36.8% from baseline over 12 weeks [6]. This trial provided early pharmacokinetic data showing that adolescents metabolize evolocumab similarly to adults, supporting the use of standard adult dosing in this age group.

RUTHERFORD-2 Subgroup Data

The RUTHERFORD-2 trial (N=329 adults) established the adult HeFH efficacy profile, but a post-hoc subgroup review noted comparable percentage LDL-C reductions across patients categorized by age at enrollment [7]. While that subgroup did not include patients under 18, the biological consistency of PCSK9 inhibition across age groups reinforces the pharmacological rationale for adolescent use.

Guideline Positions on Adolescent PCSK9 Use

AHA 2018 Scientific Statement

The 2018 American Heart Association Scientific Statement on familial hypercholesterolemia explicitly addresses PCSK9 inhibitor use in children and adolescents. The statement notes: "PCSK9 inhibitors may be considered in children and adolescents with HoFH or severe HeFH who have not reached LDL-C targets despite maximally tolerated statin therapy plus ezetimibe" [8].

The same document recommends LDL-C targets of <130 mg/dL for adolescents with HeFH, and <100 mg/dL where ASCVD risk factors cluster [8].

NLA and EAS Recommendations

The National Lipid Association (NLA) and European Atherosclerosis Society (EAS) have published parallel guidance. The EAS Consensus Panel states that PCSK9 inhibitors are "appropriate second-line agents in pediatric FH patients aged 10 years and above when statin plus ezetimibe is insufficient," citing evidence from the HAUSER program and the earlier Phase 2 pediatric HoFH work [9].

Endocrine Society Clinical Practice Guideline

The Endocrine Society's 2017 dyslipidemia guideline recommends initiating statin therapy in FH patients as young as 8 to 10 years and acknowledges PCSK9 inhibitor add-on therapy in cases of severe or refractory disease [10]. The guideline does not set a minimum age for PCSK9 therapy in FH but calls for individualized risk assessment.

Patient Selection: Who Qualifies for Off-Label Evolocumab at Ages 12 to 17

Selecting adolescents appropriately is the cornerstone of responsible off-label prescribing. The following framework reflects current expert consensus and trial eligibility criteria.

Step 1: Confirm the FH Diagnosis

A diagnosis of HeFH should be established using the Dutch Lipid Clinic Network (DLCN) score, the Simon Broome criteria, or genetic testing identifying a pathogenic LDL receptor (LDLR), apolipoprotein B (APOB), or PCSK9 gain-of-function variant. An untreated LDL-C above 190 mg/dL in an adolescent, combined with a first-degree relative with documented premature ASCVD or FH, typically meets Simon Broome criteria [11].

Step 2: Optimize Background Therapy First

Before adding evolocumab, the adolescent should have completed at least a 3-month trial of the maximum tolerated statin (rosuvastatin 20 to 40 mg or atorvastatin 40 to 80 mg) plus ezetimibe 10 mg daily. Trials confirm this combination can lower LDL-C by 50 to 60% on its own [12]. Evolocumab is added when LDL-C remains above target despite this regimen.

Step 3: Assess Cardiovascular Risk Modifiers

Factors that push toward earlier PCSK9 initiation include:

• LDL-C persistently above 190 mg/dL on maximally tolerated therapy
• Family history of premature ASCVD (first-degree relative with event before age 55 in men, 65 in women)
• Presence of subclinical atherosclerosis on carotid intima-media thickness (cIMT) ultrasound
• Concurrent diabetes, hypertension, or obesity (BMI >95th percentile for age and sex)
• HoFH diagnosis at any LDL-C level

Step 4: Shared Decision-Making and Consent

Off-label use requires documented informed consent or assent. Parents and the adolescent patient should understand the off-label status, the available trial evidence, insurance coverage limitations, and the injection schedule. A pediatric lipid specialist or pediatric cardiologist should be involved in the prescribing decision when possible.

Dosing in Adolescents Ages 12 to 17

No pediatric-specific dose has been formally approved for HeFH in this age group. Clinicians generally apply adult dosing based on the HAUSER-RCT protocol and the Phase 2 HoFH data.

Recommended Off-Label Dose

• 140 mg subcutaneous every 2 weeks, administered with the single-use autoinjector or prefilled syringe
• 420 mg subcutaneous once monthly, administered as three consecutive 140 mg injections within 30 minutes, or using the SureClick 420 mg autoinjector

The monthly regimen was used in the pediatric HoFH Phase 2 trial [6] and is often preferred for adolescents who find the biweekly schedule burdensome.

Injection Technique Training

Training should confirm the adolescent can self-inject or that a parent can administer injections reliably. Injection sites include the abdomen (avoiding the 2-inch radius around the navel), the outer thigh, or the upper arm. Rotating sites reduces local reactions [1].

Body Weight Considerations

Evolocumab pharmacokinetics in the HAUSER-RCT were not substantially altered by body weight across the pediatric cohort, and no weight-based dose adjustment is currently recommended [4]. Adolescents with obesity should receive the same dose as those at normal weight.

Safety Profile in the 12 to 17 Age Group

Adverse Events from Controlled Trials

The HAUSER-RCT 24-week data and the HAUSER-OLE 76-week extension provide the most rigorous safety data available for adolescents. Combined, the adverse event profile was as follows [4] [5]:

• Injection-site reactions: approximately 3 to 5% of evolocumab-treated participants vs. Approximately 1% placebo
• Nasopharyngitis: 12.8% evolocumab vs. 13.3% placebo (not meaningfully different)
• Influenza-like illness: 5.1% evolocumab vs. 3.3% placebo
• Serious adverse events attributed to evolocumab: 0 cases in either trial period
• Neurocognitive adverse events: none reported in the pediatric cohort (a concern flagged in earlier adult trials, later found non-significant in FOURIER-OLE) [13]

Lipid and Metabolic Monitoring

After initiating evolocumab, obtain a fasting lipid panel at 4 to 8 weeks. If LDL-C has fallen to target, recheck every 3 to 6 months. Liver function tests are not routinely required with PCSK9 inhibitors (unlike statins), but baseline ALT and AST are reasonable before adding any new agent to a statin-containing regimen [10].

Long-Term Growth and Hormonal Effects

No trial has demonstrated that evolocumab interferes with pubertal development, linear growth, or sex hormone levels in adolescents. The HAUSER-OLE assessed Tanner staging at each visit and found no difference in pubertal progression between treated participants and age-matched normative data [5]. This is reassuring but not definitive given the 76-week observation window.

Insurance Coverage and Prior Authorization for Off-Label Use

Coverage for off-label evolocumab in adolescents varies by payer. Most major insurers require a prior authorization that documents:

1. A confirmed FH diagnosis (genetic or clinical criteria met)
2. An LDL-C level on the claim supporting medical necessity
3. Documentation of a failed adequate trial of statin plus ezetimibe
4. A letter of medical necessity from the prescribing physician, ideally cosigned by a specialist

The manufacturer (Amgen) offers the Repatha SupportPlus program, which provides copay assistance and free drug for qualifying uninsured patients. Current program details are at Amgen's patient support portal, though eligibility criteria change periodically and should be verified directly.

Some payers apply the adult PCSK9 inhibitor criteria to adolescent cases, which typically require ASCVD or HeFH with LDL-C above 70 mg/dL despite maximally tolerated statin therapy. Others apply a stricter "on-label only" policy for patients under 18 and require a peer-to-peer review [14].

Comparing Evolocumab to Alirocumab in Adolescents

Alirocumab (Praluent, Sanofi/Regeneron) received FDA approval in 2021 for HeFH in patients aged 8 and older following the ODYSSEY KIDS trial, giving it a broader labeled pediatric indication than evolocumab [15]. For adolescents aged 12 to 17 with HeFH, alirocumab may therefore be the preferred on-label option when a PCSK9 inhibitor is indicated, avoiding the off-label classification entirely.

Clinicians may still choose evolocumab when:

• Prior authorization has been granted and the patient is tolerating it
• The 420 mg monthly autoinjector is preferred over alirocumab's 75/150 mg biweekly schedule
• HoFH is the indication (both agents are approved for HoFH in adolescents 13 and older)

The LDL-C reduction magnitude is comparable between agents. ODYSSEY KIDS showed a placebo-adjusted LDL-C reduction of 35.3% with alirocumab in pediatric HeFH [15], while HAUSER-RCT showed 44.5% with evolocumab [4]. Head-to-head adolescent data do not exist.

Clinical Workflow: Starting Evolocumab Off-Label at Ages 12 to 17

The following sequential steps reflect guideline recommendations and standard lipid clinic practice.

1. Confirm FH diagnosis using DLCN, Simon Broome, or genetic testing [11]
2. Obtain baseline labs: fasting lipid panel, glucose, ALT, AST, CK
3. Optimize statin dose to maximum tolerated and add ezetimibe 10 mg; recheck lipids at 6 to 8 weeks [12]
4. Document failure to reach target (LDL-C >130 mg/dL for HeFH or >100 mg/dL with additional risk factors)
5. Refer to or consult pediatric lipid specialist if not already involved
6. Obtain informed consent/assent documenting off-label status and available evidence
7. Submit prior authorization with diagnosis codes, lab values, and letter of medical necessity
8. Train patient and caregiver on autoinjector technique and injection-site rotation
9. Recheck fasting lipid panel at 4 to 8 weeks post-initiation
10. Monitor every 3 to 6 months once stable; reassess cardiovascular risk annually

Special Populations Within the 12 to 17 Age Group

Patients with HoFH

Adolescents aged 13 to 17 with HoFH are on-label for evolocumab 420 mg monthly. Those aged 12 with HoFH fall just outside the labeled indication; the same adult dose is used off-label, supported by the Phase 2 HoFH pediatric data in which the youngest participants were 13 years old [6]. Clinical judgment should guide use in 12-year-olds with HoFH.

Statin-Intolerant Adolescents

Statin intolerance in adolescents is less common than in adults but does occur. When a child cannot tolerate any statin dose due to myalgia confirmed by CK elevation or rechallenge, ezetimibe alone plus evolocumab may be considered, though this bypasses the standard statin step. The EAS guidelines accept this pathway in documented statin intolerance [9].

Adolescents with Comorbid Diabetes

Type 1 diabetes plus HeFH creates compounded ASCVD risk. Data from adult trials, including the FOURIER trial (N=27,564), showed evolocumab reduced major adverse cardiovascular events by 15% relative risk reduction versus placebo in adults, an effect independent of baseline diabetes status [16]. Extrapolating this to adolescents is speculative, but the risk burden in a teenager with both conditions may justify earlier PCSK9 use.

Summary of LDL-C Targets and When to Escalate

| Clinical Setting | LDL-C Target | Action if Not Reached | |---|---|---| | HeFH, no additional risk factors | <130 mg/dL | Add ezetimibe, then PCSK9 inhibitor | | HeFH plus diabetes or hypertension | <100 mg/dL | Escalate earlier, consider PCSK9 at 3 months | | HoFH (on-label at age 13+) | <100 mg/dL or 50% reduction | Evolocumab 420 mg monthly on-label | | Subclinical atherosclerosis (elevated cIMT) | <100 mg/dL | Expedited escalation to PCSK9 |

Targets are drawn from the 2018 AHA Scientific Statement on FH [8] and the NLA Pediatric FH recommendations.